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Structural basis for species-selective targeting of
Hsp90 in a pathogenic fungus
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Sharanya Chatterjee6, Richard Trilles3, Jinglin L. Xie1, Damian J. Krysan7, Susan Lindquist2,8, John A. Porco Jr.3,
Utpal Tatu6, Lauren E. Brown 3, Juan Pizarro 4 & Leah E. Cowen1
New strategies are needed to counter the escalating threat posed by drug-resistant fungi. The
molecular chaperone Hsp90 affords a promising target because it supports survival, virulence
and drug-resistance across diverse pathogens. Inhibitors of human Hsp90 under develop-
ment as anticancer therapeutics, however, exert host toxicities that preclude their use as
antifungals. Seeking a route to species-selectivity, we investigate the nucleotide-binding
domain (NBD) of Hsp90 from the most common human fungal pathogen, Candida albicans.
Here we report structures for this NBD alone, in complex with ADP or in complex with known
Hsp90 inhibitors. Encouraged by the conformational flexibility revealed by these structures,
we synthesize an inhibitor with >25-fold binding-selectivity for fungal Hsp90 NBD. Com-
paring co-crystals occupied by this probe vs. anticancer Hsp90 inhibitors revealed major,
previously unreported conformational rearrangements. These insights and our probe’s
species-selectivity in culture support the feasibility of targeting Hsp90 as a promising anti-
fungal strategy.
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Fungal pathogens are major contributors to human morbidityand mortality, infecting billions of people worldwide andkilling in excess of 1.5 million per year1. The most vulner-
able are individuals with compromised immune systems,
including those undergoing chemotherapy, recipients of solid
organ or hematopoietic stem cell transplants, and those infected
with HIV. Candida albicans is a common commensal member of
the human mucosal microbiome, but it is also the most frequent
cause of invasive fungal infections in hospitalized patients, with
mortality rates for disseminated disease approaching 40%, even
with current treatments2. The development of drugs with selec-
tive activity against fungi has been hampered by the close evo-
lutionary relationship between fungi and their human hosts3. An
armamentarium of only three broadly deployed drug classes
currently exists, and the frequent emergence of resistance makes
cure of invasive fungal infections often unachievable. New agents
with non-cross-reactive modes of action and non-overlapping
toxicities are urgently needed4.
A promising strategy to enhance the efficacy of established
antifungals and improve clinical outcome is the co-targeting of
regulators of fungal stress responses5. We previously established
that the evolutionarily ancient, highly conserved molecular cha-
perone Hsp90 promotes antifungal drug tolerance and the evo-
lution of drug resistance in species of Candida and Aspergillus6–8.
Hsp90 is essential in all eukaryotes where it regulates the form
and function of diverse client proteins, many of which are key
signal transducers9. Hsp90 enables drug resistance via multiple
molecular mechanisms, most notably through the stabilization of
the stress-activated protein phosphatase calcineurin and multiple
components of Pkc1 mitogen-activated protein kinase (MAPK)
cell wall integrity pathway6,8,10,11. Hsp90 also serves as the pre-
viously enigmatic thermal sensor that controls temperature-
dependent morphogenetic switching in C. albicans12, a key factor
contributing to the organism’s virulence13,14. In animal models,
limiting Hsp90 function restores sensitivity in drug-resistant
fungal pathogens, impedes the evolution of drug resistance, and
leads to clearance of otherwise lethal infections7,8,12,15. Unfortu-
nately, compromise of host Hsp90 function with human
homolog-optimized drugs (currently being tested in patients with
cancer) comes with prohibitive side effects in the context of
systemic fungal infections7,16. Thus, while fungal Hsp90 serves as
a promising therapeutic Achilles heel, the utility of targeting it
depends on whether sufficient inhibitor selectivity can be
achieved to avoid compromise of its human homolog5,17.
The ability to inhibit nucleotide binding within the Bergerat
fold present in Hsp90’s N-terminal domain was initially estab-
lished by two structurally unrelated macrocyclic natural products,
the resorcinylic acid lactone radicicol and the benzoquinone
ansamycin geldanamycin18,19. With the goal of disrupting
Hsp90’s unique role in enabling oncogenesis, multiple structure-
guided anticancer drug development programs have yielded a
diverse array of inhibitor chemotypes20–22. Utilizing a variety of
high affinity binding modes, these compounds all mimic the
unusual conformation adopted by ATP upon binding within the
chaperone’s nucleotide-binding domain (NBD) and inhibit ATP
binding and hydrolysis, thereby blocking chaperone function23.
Consistent with its evolutionarily ancient and essential role in
maintaining eukaryotic protein homeostasis, Hsp90 is highly
conserved across phylogenetic kingdoms. For bacterial, yeast and
human Hsp90, an ordered three-state cycle of conformational
changes associated with the hydrolysis of ATP is fundamental to
the protein’s chaperoning activity24. However, the equilibria
between these states and the intrinsic ATPase activity of the
isoforms are highly species-specific25. The disparity has been
hypothesized to reflect “evolutionary tuning to meet the client
protein and metabolic environment of an organism”26. An
additional layer of conformational regulation is provided by a
suite of co-chaperones and accessory proteins, which also varies
in composition across species. These proteins physically associate
with Hsp90 to modulate its client-protein binding and the con-
formational changes associated with its chaperoning cycle27.
Thus, despite a high degree of primary sequence conservation,
functionally important conformational differences have been
demonstrated between the Hsp90 isoforms expressed in humans
and the model fungus Saccharomyces cerevisiae27. To date,
however, no Hsp90 structural studies have been performed in
pathogenic fungi such as C. albicans.
Seeking to target potential species-dependent differences in
conformation or flexibility within the ATP-binding pocket of
Hsp90, we pursue an iterative chemo-structural approach to
achieve fungal-selective inhibition. We first solve the structure of
the C. albicans Hsp90 N-terminal NBD, alone and in complex
with several known Hsp90 inhibitors. The insights gained helped
guide synthesis of a fungal-selective probe molecule,
CMLD013075 (1). This probe is then co-crystalized with the
NBD to reveal a surprising, previously unreported binding-site
rearrangement permitting accommodation of the ligand. The
unique binding mode observed for our probe and the structural
flexibility of the fungal NBD suggest a promising path to selec-
tivity despite high conservation at the primary sequence level.
Our findings provide proof-of-principle for the feasibility of
selectively targeting fungal Hsp90, while the biological activities
of our probe support the therapeutic potential of targeting this
key molecular hub to counter the escalating problem of drug-
resistant fungal infections4.
Results
Unique features of C. albicans Hsp90. To identify potentially
exploitable differences in the Hsp90 expressed by a fungal
pathogen vs humans, we determined the crystal structure of the
C. albicans Hsp90 N-terminal domain, which includes the
nucleotide-binding pocket targeted by all Hsp90 inhibitors in
clinical development28,29. We obtained structures for the domain
under three conditions: apo (unliganded), in complex with ADP,
and in complex with the prototypical inhibitor radicicol (Fig. 1a,
Supplementary Table 1). Despite the presence of different ligands,
overlay of the three crystal structures showed an almost identical
conformation for this domain with a root mean square deviation
(r.m.s.d.) of 1.32 Å or less over all atoms (Fig. 1a and Supple-
mentary Table 2). Nonetheless, localized structural differences
between the apo and liganded complexes were observed in the
loop between α-helices 4 and 5 (residues Gly97 to Thr104), a
region on the edge of the ATP binding site (Supplementary
Figure 1). A portion of this region also differed between the
fungal protein and its human homolog, amid otherwise very
similar structures (Fig. 1b, c, upper panels). In previously
reported human apo structures, residues 104–111 adopt either an
open (PDB: 1YES) or closed (PDB: 1YER) loop conformation; in
the C. albicans apo structure, the corresponding region (94–101)
adopts an open loop conformation (Fig. 1c, upper panel). Overall
comparison between both human apo structures (open and
closed) and the fungal N-terminal domain showed no major
differences, with main-chain atom r.m.s.d. of 1.02 and 1.15 Å,
respectively. Global structural similarity between fungal and
human Hsp90 was also observed when comparing the chaperone-
ADP and -radicicol complexes (Fig. 1b, middle and lower panels).
Additionally, the N-terminal domain of C. albicans Hsp90 shares
the same architecture at the nucleotide-binding site, which
interacts with both ADP and radicicol through hydrogen-bond
interactions at the same amino acids (Asp92 and Thr174, Fig. 1c,
middle and lower panels).
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Given the structural similarities between human and C.
albicans Hsp90 NBD, we asked whether the core ATPase activity
of purified full-length homodimers from each species would also
be conserved. The dissociation constant (Kd) for ATP of C.
albicans Hsp90 was similar to that previously reported for S.
cerevisiae Hsp90 (125 vs 132 µM), but somewhat lower than that
reported for human Hsp90 (240 µM; Supplementary Figure 2a,
2d). The ATPase activity of C. albicans Hsp90 obeyed
Michaelis–Menten kinetics (Supplementary Figure 2b and 2c),
yielding values for catalytic efficiency similar to that reported for
S. cerevisiae (11.6 × 10–5 vs 15.6 × 10–5) but more than twofold
higher than that reported for human Hsp90 (4.6 × 10–5;
Supplementary Figure 2d). At the level of biochemical activity,
therefore, a difference is apparent between C. albicans Hsp90 and
its mammalian counterpart despite extensive sequence conserva-
tion within the NBD.
Increased conformational flexibility in C. albicans Hsp90.
Seeking to reconcile apparent structural conservation with dis-
parity in ATPase activity, we probed the conformational flex-
ibility of the C. albicans NBD by solving structures of the domain
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Fig. 1 Structure of C. albicans Hsp90 nucleotide-binding domain (NBD) in apo and ligand-bound states. a Ribbon representation of crystal structures
determined for C. albicans Hsp90 NBD in the non-ligand-bound or apo state (green), ADP-bound state (yellow) and in complex with radicicol (magenta).
The ligands ADP and radicicol are represented as sticks and color-coded according to their heteroatom composition. An overlay of all three structures is
also presented at the far right. b Ribbon representation of crystal structures determined for C. albicans NBD (darker shades) in the non-ligand-bound or apo
state (top panel, green), ADP-bound state (middle panel, orange), and in complex with radicicol (lower panel, magenta). Structures for human Hsp90 NBD
(lighter shades) are overlaid. The ligands ADP and radicicol are represented as sticks and color-coded according to their heteroatom composition. The
main-chain atom r.m.s.d. for the superpositions is indicated in parentheses for each overlaid pair. c Detailed view of superpositions encompassing the
region of the ligand-binding site. The top panel provides a detailed view of the region Asn94–Lys 101 in C. albicans and human apo structures, two human
conformations are shown open (lighter green; PDB id. 1YES) and closed (darker green; PDB id. 1YER). The middle and bottom panels depict a detailed view
of the residues which hydrogen-bond with ADP and radicicol, respectively, in both C. albicans and human Hsp90 NBD
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in complex with two clinically relevant Hsp90 inhibitors, SNX-
2112 (Fig. 2a, Supplementary Table 1) and AUY922 (Fig. 2b,
Supplementary Table 1). These compounds were chosen because
previously reported human Hsp90 structures had shown distinct
conformational changes in the region defined by Hsp90 residues
104–111 in co-crystals with these ligands30. While the human
Hsp90-AUY922 complex shows an apo-like, closed-loop con-
formation, the human NBD in complex with SNX-2112 shows an
extended α-helical conformation. This conformation exposes a
hydrophobic pocket that has been previously characterized in
human Hsp9031. Interestingly, compounds that induce a helical
conformation of the 104–111 region show orthologue selectivity
within the human Hsp90 family, binding poorly to Grp94 and
Trap-1.
To correlate structural insights with the relative binding affinity
for compounds, we used a fluorescence polarization (FP)-based
competition approach that allows quantitation of ligand binding
in assays utilizing purified NBD proteins or whole-cell lysates.
Use of purified proteins allows determination of actual ligand
dissociation constants for specific NBD32. Use of lysates
interrogates overall ligand binding by Hsp90 in its native
complexes with co-chaperones and in the case of human cells,
the mixture of Hsp90 isoforms present in the lysate. Lysate
experiments can only provide assay-dependent relative EC50
values for inhibitors, but may be more relevant to selectivity at the
whole-cell level. To avoid problems with auto-fluorescence typical
of lysate, we synthesized a previously reported, red-shifted Cy3B-
geldanamycin conjugate to use as the FP probe in both
configurations of the assay33. Importantly, using this probe with
purified human NBD protein yielded an inhibitory Ki for
geldanamycin consistent with previously reported values for
full-length recombinant Hsp90α34. In our FP assay, SNX-2112
showed threefold higher affinity for the fungal than human
Hsp90-binding domain (Fig. 2a, right panel and Supplementary
Figure 3a, 3b). In lysates, the compound displayed even greater
fungal selectivity, but the improvement may have resulted from
the relatively poor affinity of SNX-2112 for Grp94 which is
reported to be present in almost equimolar concentration to
Hsp90 α/β in HEPG2 cells from which the human lysate was
prepared (Supplementary Figure 3b and 3c)35.
The structure of the C. albicans NBD–SNX-2112 co-crystal
showed that the aminobenzamide and cyclohexanol portions of
SNX-2112 occupy the adenosine region of the ATP-binding
pocket, making similar polar contacts with the fungal Hsp90 as
those seen in the human structure; overall both complexes
showed considerable structural similarity (r.m.s.d. 1.0 Å, main-
chain atoms) including almost identical poses for SNX-2112
(Fig. 2a). However, in the fungal NBD, the dihydroindazolone
moiety of SNX-2112 induced a localized structural rearrangement
of the Val93–Ser102 (103–112 in human Hsp90) region distinct
from the one observed in the human complex structure. Unlike
the extended α-helix observed for the human NBD in complex
with SNX-2112, the C. albicans NBD adopted a bulged-out loop
conformation with a shortening of α-helix 4 (Fig. 2a, right panel).
A similar conformation was previously described for a complex of
T. brucei Hsp90 NBD with SNX-2112 complex (PDB: 3OPD).
Interestingly, the Hsp90 in this organism showed increased
affinity for SNX-211236. An overlay between C. albicans NBD apo
and SNX-2112 structures further demonstrates the significance of
the structural rearrangement within the Val93–Ser102 region
upon binding to SNX-2112, as this region shows the largest
differences between both structures (Fig. 2c and Supplementary
Figure 1). The plasticity of the C. albicans Hsp90 ATP-binding
site appears to be an important element in understanding
differences in binding affinity for ortho-benzamide-type Hsp90
inhibitors like SNX-2112, due to the highly localized nature of the
structural differences between the liganded C. albicans and
human chaperones, and between the C. albicans liganded and apo
structures.
In contrast to SNX-2112, the structure of C. albicans Hsp90
NBD in complex with AUY922 was different from all previously
reported structures for an Hsp90 of any species, revealing a large
structural rearrangement that extended beyond the nucleotide-
biding site (Fig. 2b–d). This fungal co-crystal structure contrasts
with a previously reported human NBD-AUY922 complex
structure, which adopts a closed-loop apo conformation (PDB:
2VCI)37. Remarkably, the large structural rearrangements
observed in the C. albicans AUY922 complex were accompanied
by very high binding affinity for the compound, although less
than that observed for the human NBD (Fig. 2b, right panel and
Supplementary Figure 3b). As with SNX-2112, the high affinity of
AUY922 for human Hsp90 NBD also appears to have been
obscured somewhat in HEPG2 lysate by the lower affinity of
Grp94 for this compound (Supplementary Figure 3b and 3c). An
overlay of the fungal and human complexes highlights the extent
of the structural changes associated with AUY922 binding to C.
albicans NBD (Fig. 2b and Supplementary Figure 1, r.m.s.d. 3.8 Å,
main-chain atoms). The observed conformational change extends
beyond the nucleotide-binding site to include the N-terminal β-
strand (β1) and helix (α1), and the lid subdomain comprising
residues 94–126 (including helices α5 and α6) (Figure S4a). The
loss of β1 also leads to a shortening of the adjacent strand (β6)
and repositioning of the loop connecting β5-β6 (Supplementary
Figure 4a).
Despite major structural differences between the C. albicans
and human Hsp90 complexes with AUY922, the ligand maintains
the majority of polar and non-polar contacts in each, adopting
nearly identical orientations with the exception of the morpholine
substituent (Fig. 2b, Supplementary Figure 4a and 4b). In
complex with human Hsp90α, the morpholine points away from
the chaperone into the solvent, engaging in limited interactions
with the host protein at residues Thr109 and Gly135. In the C.
albicans complex, the heterocycle is flipped ~180° towards the
protein core, engaging in contacts with residues Asn95, Gly124
and Phe123 (Supplementary Figure 4b). The conformational
changes induced by AUY922 binding in C. albicans
Hsp90 suggest a far greater degree of conformational flexibility
for the fungal chaperone compared to its human homolog.
To better understand the roles of the NBD’s structural elements
in ligand-binding, we overlaid the C. albicans Hsp90 apo and
AUY922 structures (Fig. 2c, right). As previously noted, the C.
albicans NBD-AUY922 complex showed a large conformational
change leading to major overall differences with respect to the apo
structure (r.m.s.d. 3.47Å, all atoms). Upon AUY922 binding,
residues 94–101 adopt a helical conformation that fuses helices 4
and 5 (Fig. 2d). This fused helical element peels the lid region away
from the ATP-binding site to accommodate positioning of
AUY922’s morpholine ring. This repositioning is accompanied by
disappearance of the N-terminal β-strand (β1), affecting β6 and its
preceding loop. Despite this clear change, the rest of the protein’s
structure in both the apo and AUY922 complexes is almost
identical. The portion of the C. albicans NBD which interacts with
the base moiety of ATP, defined by residues from the β-sheet (β2 to
β5) and helices α2, α3, α8, and α9, is extremely rigid. Furthermore,
this rigid region showed no significant differences across all of the
co-crystal structures we solved for the fungal NBD (Supplementary
Figure 1). Considered together, our structural observations define
the conformationally mobile portions of C. albicans NBD that
participate in the binding of specific ligands. Most importantly, the
magnitude of structural reorganization observed upon binding of
AUY922 indicated a much higher degree of conformational
flexibility in the fungal than human Hsp90 NBD.
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Fig. 2 Comparison of inhibitor-bound structures for C. albicans vs human Hsp90 NBD. a Detailed view of the binding mode of SNX-2112 to C. albicans
Hsp90 nucleotide-binding domain (NBD) (dark blue), overlaid with a human Hsp90α NBD structure in complex with SNX-2112 (light blue; PDB id. 4NH7).
Several of the C. albicans Hsp90 residues interacting with the compound are identified, and the conformation of the 93–102 region is indicated by a dotted
rectangle. Binding affinities for the compound were determined by equilibrium competition FP assay using purified human and fungal NBDs. Ki values are
indicated below the structures. The mean ± SEM of three independent experiments is presented. b Detailed view of the binding mode of AUY922 to
C. albicans Hsp90 NBD (orange), overlaid with a human Hsp90α NBD structure in complex with the same compound (light orange; PDB id. 2VCI). Several
C. albicans Hsp90 residues interacting with the compound are identified. The helical conformation of the 93–102 region is indicated by a dotted rectangle.
Hsp90 NBD binding affinities were determined as described for panel a. The mean ± SEM of three independent experiments is presented. c Inhibitor-
induced conformational changes in C. albicans NBD. Ribbon representation of C. albicans Hsp90 NBD bound to Hsp90 inhibitors SNX-2112 (left image) and
AUY922 (right image). Apo structure (green) is overlaid. Compounds are represented as sticks and color-coded according to heteroatom composition. A
detailed view of the conformational differences in the 93–102 region between apo and SNX-2112 bound crystal structures is provided; SNX-2112 is shown as
sticks and a semitransparent yellow surface. d Views from different angles of the C. albicans Hsp90 NBD in its apo and AUY922-bound states. Overlays of
the crystal structures are shown in cartoon/ribbon representation. Secondary structure elements are color-coded to highlight the conformational changes
associated with AUY922 binding; dotted arrows indicate the direction of the movement of secondary structure elements. The outline of the apo surface is
indicated by a black line, and the AUY922 position is indicated as a semitransparent yellow sphere representation. Source data for the determination of all
inhibitory constants are provided as a source data file.
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Semi-synthesis of fungal-selective Hsp90 inhibitors. Disparity
between the ligand-induced conformational changes we identified
in fungal vs human NBDs encouraged further work to synthesize
fungal-selective inhibitors. To identify the most promising scaf-
fold from which to begin, we tested a panel of Hsp90 inhibitor
chemotypes for their ability to inhibit fungal growth. We used a
strain of S. cerevisiae in which the genes encoding both isoforms
of its endogenous Hsp90 (HSP82 and HSC82) have been dis-
rupted and growth is dependent upon C. albicans Hsp90
expressed from a plasmid. The natural product radicicol was the
only Hsp90 inhibitor found to significantly inhibit growth of our
engineered fungal strain (Supplementary Figure 5a, 5b). Our
structural studies had demonstrated considerable ligand-induced
flexibility within the NBD of fungal Hsp90, including an ability of
the fungal, but not human, NBD to significantly rearrange to
accommodate AUY922, an inhibitor which conserves the resor-
cinylic substructure of radicicol. As an approach to exploit this
apparent flexibility, we pursued the introduction of steric bulk to
radicicol via oxime derivatization (a strategy previously employed
for metabolic stabilization of the compound)38,39. We began by
investigating the binding to C. albicans vs human Hsp90 of
KF58333, a previously described radicicol oxime (Fig. 3a).
To monitor relative Hsp90-binding affinities, we again used an
FP-based competition approach in whole-cell lysates. We
observed potent binding for KF58333, but nearly equivalent
EC50 values for both human and Candida Hsp90 (7–10 nM)
(Fig. 3b and Supplementary Table 3). Presumably the oxime
substituent in KF58333, which had been optimized to preserve
activity in humans, is not sufficiently bulky to hinder binding of
the compound. To address this, we next generated a small set of
known (2)40,41, (8) (USPTO Patent Application 20100292218)
and novel oxime analogs (3–7) through the direct chemical
modification of radicicol42. The compounds were prepared using
standard conditions with commercially available alkoxyamines
varying in size and substitution (Fig. 3c and Supplementary
Methods). Also included in the set was an analog, CMLD013075
(1) derived from the structurally related des-chlorinated natural
product monocillin I (Fig. 3c), which is roughly equipotent to
radicicol as an Hsp90 inhibitor in plants43. By FP assay, we found
a moderate (1.4- to 4.6-fold) gain in fungal selectivity for several
of our new oxime analogs in binding Hsp90 in whole-cell extracts
prepared from C. albicans (SC5314) compared to HEPG2, a
human cancer cell line (Fig. 3b). Although our design efforts were
inspired primarily by structural and biological data pertaining to
radicicol, we serendipitously discovered that the most selective
inhibitor was monocillin-derived CMLD013075. This compound
exhibited superior fungal selectivity over all other analogs tested
by FP lysate assay, with an EC50 of ~500 nM in C. albicans lysate
translating to a normalized 4.6-fold selectivity factor (Fig. 3b and
Supplementary Table 3). Overall, our compound series supports a
model in which the steric bulk of larger oximes can limit binding
to the less flexible human Hsp90 NBD, yet still maintain, if not
improve, fungal Hsp90-binding activity.
A critical consideration in the development of an effective
antifungal is not just target binding, but also access to the
target across microbial cell membranes and cell walls. There-
fore, we evaluated the potency and selectivity of oxime analogs
using drug susceptibility assays. We used strains of S. cerevisiae
where both endogenous genes encoding isoforms of Hsp90
have been disrupted and growth is solely dependent upon C.
albicans or human Hsp90 isoforms. All our oxime derivatives,
including CMLD013075, displayed greater potency in limiting
fungal proliferation than geldanamycin and KF58333 (Fig. 3d).
Consistent with selectivity findings by FP, CMLD013075 was
more active against a yeast strain engineered to express C.
albicans Hsp90 than isogenic strains expressing either human
Hsp90α or Hsp90β proteins. The converse was true of radicicol
(Fig. 3e).
Hsp90 residues key to the fungal selectivity of CMLD013075.
To identify molecular contacts contributing to the relative
selectivity of CMLD013075 for C. albicans Hsp90, we solved a co-
crystal structure of the compound bound within the protein’s N-
terminal domain (Fig. 4a). Structural analysis revealed a sub-
stantial conformational rearrangement of the NBD associated
with binding of the derivative, with an r.m.s.d. of 1.86 Å upon
comparison to a radicicol co-crystal structure (Supplementary
Table 2). Conformational rearrangement was associated with an
inhibitory constant (Ki) by FP assay of 7.7 nM for binding of
CMLD013075 to the fungal NBD and selectivity over binding to
the NBDs of human Hsp90 and Grp94 of ~28- and ~5-fold
respectively (Fig. 4c). The binding affinity of radicicol could not
be assessed by FP due to its Michael reactivity and inactivation of
the compound by thiol-reducing agent in the assay buffer38,39.
The compound-induced conformation involved major move-
ments of the N-terminal β-strand and repositioning of the lid
subdomain that included α-helices 1, 5–7 and their linking loops
(Supplementary Figure 1 and 6). These structural changes are
accompanied by a partial remodeling of the ATP-binding site to
accommodate the bulkier p-methoxybenzyl moiety of this com-
pound (Fig. 4b and Supplementary Figure 8a, S8b). The macro-
cyclic portion of CMLD013075 occupies a position identical to
that observed in the radicicol complex structure, with the oxime-
linked p-methoxybenzyl group participating in several hydro-
phobic interactions as well as an apparent N-H⋯π bond to Asn40
(Fig. 4d).
Given the significant structural rearrangements associated with
binding of CMLD013075 and AUY922 to C. albicans Hsp90, we
next sought to directly compare these changes with respect to
each other and to the apo structure (Supplementary Figure 6).
Both the CMLD013075 and AUY922 complexes show similar
changes in several secondary structure elements, such as the
disappearance of the N-terminal β-strand (β1), the extension and
tilting of helix α1, and the displacement of the lid subdomain
(Supplementary Figure 6). However, in the CMLD013075
complex residues 94–101 adopt a bulged-in loop conformation,
associated with a movement of the lid subdomain that appears
essential to accommodate the p-methoxybenzyl group within the
ATP-binding site (Supplementary Figure 8b). This conforma-
tional change differs considerably from the AUY922-induced
structural rearrangement that involved the fusion of helices 4 and
5, and repositioning of the lid subdomain to accommodate
AUY922’s morpholine ring (Supplementary Figure 6).
To rationalize the enhanced selectivity of CMLD013075 for
fungal Hsp90, we evaluated each amino acid residue that differed
between the C. albicans and human NBD and assessed the
individual contributions of these residues to local conformation
by comparing their H-bond networks. In this way, we identified
several residues within the fungal NBD that might affect the
protein’s conformation (Fig. 4e). We tested their importance by
generating three C. albicans Hsp90 variants with the native fungal
residues changed to their corresponding human residues (Fig. 5a,
b). The first variant was a single substitution, replacing fungal
threonine with human glutamine at position 12 (Thr12Gln)
located between the N-terminal β-strand and α-helix. This
substitution was predicted to affect the flexibility of the Gly94-
Gly100 loop linking helices 4 and 5, thus potentially limiting
movement of the lid region and N-terminus seen in the
CMLD013075 complex structure. The second variant involved
two amino acid changes within α-helix 7 (Leu130Ala and
Phe131Tyr) which were predicted to impact contact with the
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para-methoxybenzyl substituent. The final variant also involved
two amino acid substitutions, Lys158Ser and Thr162Arg, located
within β-strand 6. This strand is adjacent to β-strand 1 in the
Hsp90 N-terminal β-sheet. To experimentally test the importance
of these residues in providing fungal selectivity, we constructed
strains of S. cerevisiae in which each of these variants constituted
the sole source of Hsp90, and then compared the antifungal
activity of radicicol and CMLD013075 against these strains. The
C. albicans Hsp90 Thr12Gln or composite Lys158Ser/Thr162Arg
substitutions did not alter the potency of either compound;
radicicol remained less potent and CMLD013075 remained more
potent against strains expressing these variants than against
strains carrying the human isoforms (Fig. 5c). In contrast, the
composite Leu130Ala/Phe131Tyr mutation increased potency of
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Fig. 3 Synthesis and characterization of fungal-selective Hsp90 inhibitors. a Structure of previously reported anticancer radicicol oxime KF58333. b Plot of
relative Hsp90-binding affinity for compounds determined in cytosolic extracts prepared from human (HEPG2) vs fungal (SC5314) cells. The relative
binding affinities for compounds were determined in cytosolic extracts prepared from human vs fungal cells by fluorescence polarization (FP) assay and are
indicated as normalized EC50 values. A red box highlights the oxime derivative CMLD013075 (1) in our panel of analogs which demonstrated the greatest
combination of potency and selectivity for fungal Hsp90. EC50 values were determined by variable slope 4-parameter curve fitting of triplicate
determinations at each concentration tested (R2 > 0.95, all curves). All fungal values were normalized by the ratio of geldanamycin EC50s measured in
human vs fungal lysate. The experiment was repeated once with quantitatively similar results. Source data for the determination of EC50 values are
provided as a source data file. c Summary of R-group substitutions and scheme for the synthesis of monocillin-derived and radicicol-derived oxime analogs
1–8. d Susceptibility testing of Hsp90 inhibitor panel using a strain of S. cerevisiae engineered to express C. albicans Hsp90 as its sole source of Hsp90.
Relative growth inhibition by each compound over a twofold dilution series of concentrations is displayed in heat-map format. Each colored box represents
the mean of duplicate determinations. Color scale for relative growth is provided in lower right of panel, green: no inhibition to black: complete inhibition.
The experiment was repeated once to confirm results. e Inhibitor sensitivity of isogenic S. cerevisiae strains engineered to express the indicated HSP90
genes as their sole source of Hsp90. Relative growth inhibition by radicicol (top) or oxime derivative CMLD013075 is displayed in the same manner and
using the same color scale as in d. The experiment was repeated as an independent biological replicate to confirm results.
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radicicol while decreasing potency of CMLD013075 relative to
wild-type C. albicans Hsp90 (Fig. 5c). In fact, these substitutions
in C. albicans Hsp90 resulted in even less sensitivity to
CMLD013075 than observed upon expression of human Hsp90
isoforms, highlighting the importance of these amino acids in
conferring fungal selectivity to the oxime.
Species-selective activity of CMLD013075 in culture. We
focused on CMLD013075 for further biological characterization,
because it possessed the most potent and selective activity in
whole-organism assays (Fig. 3d, e). We began by measuring
inhibition of C. albicans growth in culture. Both radicicol and
CMLD013075 showed comparable single-agent activity against a
laboratory strain of C. albicans (SN95) as well as a more drug-
resistant clinical isolate (CaCi-2) from an HIV-infected patient
recovered early in the course of persistent Candida infection
(Fig. 6a)6.
Next, we investigated the fungal selectivity of our Hsp90
inhibitors using standard microplate-based dye-reduction assays
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Fig. 4 Structure of Hsp90 nucleotide-binding domain (NBD) in complex with CMLD013075. a Ribbon representation of a 2.6 Å resolution crystal structure
of CMLD013075 (blue) bound to C. albicans Hsp90 NBD. Radicicol from a separate C. albicans co-crystal (magenta) is overlaid. The ligands are represented
as sticks and color-coded according to their heteroatom composition. b Detailed view of the binding mode of radicicol (top) and CMLD013075 (bottom) to
C. albicans Hsp90. A surface representation is provided and color-coded by electrostatic potential (−10 to 10kT/e blue to red color ramp). c Binding
affinities for CMLD013075 were determined by equilibrium competition FP assay using purified human Hsp90, fungal Hsp90, and human Grp94 NBDs and
are indicated as Ki values. Assays were repeated in three independent experiments. The mean ± SEM is presented. Source data for the determination of
binding affinities are provided as a source data file. d Polar contacts for the resorcinol-containing compound CMLD013075 in complex with C. albicans
Hsp90 NBD. Protein residues engaged in H-bonds or cation–π interactions are labeled, and those interactions shown as dashed black lines. e H-bond
networks of the residues selected for mutagenesis (bold residue names). Two fungal Hsp90 co-crystal structures are shown, radicicol (magenta), and
CMLD013075 (cyan). For comparison, a human structure in complex with radicicol is also displayed (PDB id. 4EGK).
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to measure concentration-dependent mammalian cytotoxicity.
CMLD013075 was >10-fold less toxic to human HEPG2 liver
cancer cells than the non-selective parent compound radicicol,
and >50-fold less toxic than ganetespib, a resorcinylic clinical
inhibitor (Fig. 6b). Cytotoxicity was also tested against Raw264.7,
mouse cancer cells of macrophage lineage, where again
CMLD013075 was much less toxic than radicicol or ganetespib
(Fig. 6b). We also examined the toxicity of CMLD013075 and
several known Hsp90 inhibitors to non-cancer cells, i.e., the non-
tumorigenic mouse fibroblast line 3T3 (Supplementary Figure 7a).
Both radicicol and CMLD013075 were less cytotoxic to 3T3 cells
than HEPG2 cells by at least 10-fold and both showed a plateau in
their dose–response curves consistent with the presence of a non-
proliferating, relatively inhibitor-insensitive population in the
contact-inhibited 3T3 line.
As an explanation for the greater activity of N-terminal Hsp90
inhibitors against cancers compared to normal tissues, it has been
reported that Hsp90 in cancer cells resides predominantly in an
activated hetero-complex form with higher inhibitor affinity44,45.
To investigate whether the binding of CMLD013075 might differ
in lysate from non-cancer cells and HEPG2 cells, we performed
FP assays with CMLD013075 and geldanamycin in lysate
prepared from quiescent 3T3 cells. Affinity for both
CMLD013075 and geldanamycin was indeed lower in 3T3 lysate
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Fig. 5 Identification of key residues for fungal selectivity. a The locations of secondary structural features observed in the respective radicicol and
CMLD013075 co-crystal structures presented in Fig. 4a are mapped above the primary sequence alignments. Red shading indicates areas of complete
sequence conservation. Black arrowheads indicate the position of the amino acids (shaded in yellow) that were changed for experiments involving
mutagenesis. Positions with variation are indicated in red letters when a particular amino acid is most common and black letters when the position is
variable. b Localization of residues mutated to examine effects on compound binding. Altered amino acids are represented as brick-colored spheres in the
C. albicans NBD-CMLD013075 co-complex structure. Side chains of each residue are depicted. The ligand is represented as sticks and color-coded
according to heteroatom composition. Light red spheres represent oxygen atoms. c Inhibitor sensitivity of isogenic S. cerevisiae strains engineered to
express the indicated wild-type and mutant Hsp90 proteins as their sole source of Hsp90. Relative growth inhibition by twofold serial dilutions of radicicol
(top) or oxime derivative CMLD013075 (bottom) is displayed in the same manner as in Fig. 3. Each colored box represents the mean of duplicate
determinations. Color scale for relative growth is provided, green: no inhibition to black: complete inhibition. The experiment was repeated as an
independent biological replicate to confirm results
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than HEPG2 lysate suggesting a relative improvement in
selectivity for fungal Hsp90 (Supplementary Figure 7b). In light
of the effects on geldanamycin affinity, however, care must be
taken in the interpretation of these results because the probe used
for these FP assays is itself geldanamycin-based. Although we
cannot resolve the potential contributions of higher Hsp90
affinity state, higher Hsp90-dependence for proliferation/survival
or even increased Grp94 content to the increased sensitivity of
HEPG2 cells to CMLD013075, it is likely that using cancer cells as
a comparator underestimates the compound’s fungal selectivity.
To determine whether CMLD013075 retained selective activity
against C. albicans in the presence of human cells, we optimized
conditions for growth of both cell types together in a co-culture
model. Established monolayers of adherent human HEPG2 cells
were infected with CaCi-2 at a multiplicity of infection (MOI) of
~0.2 and test compounds added. After 24 h of growth at 37 °C,
cultures were formalin-fixed and stained to visualize fungal
burden and underlying human cells (Fig. 6c). CMLD013075
(10 µM) was clearly more effective at limiting fungal overgrowth
than radicicol or ganetespib. Its inhibitory effect was comparable
to that of a high concentration of the widely used triazole
antifungal drug fluconazole (FL) against this moderately drug-
resistant isolate.
Selectivity reduces target-related mammalian toxicity. Com-
promise of host immune function and other target-related toxi-
cities preclude the use of non-species-selective Hsp90 inhibitors
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Fig. 6 Species-selective antifungal activity of Hsp90 inhibitor CMLD013075. a Relative growth inhibition by Hsp90 inhibitors of reference C. albicans strain
(SN95) and a clinical isolate (CaCi-2) with resistance to FL. The effect of 48-hour exposure to each inhibitor over a twofold dilution series of
concentrations is displayed in heat-map format. Each colored box represents the mean of duplicate determinations. Color scale for relative growth is
provided to far right of panel, green: no inhibition to black: complete inhibition. The experiment was repeated as an independent biological replicate to
confirm results. b Concentration-dependent inhibition of mammalian cell growth and survival after 3-day culture with Hsp90 inhibitors. Data points depict
the mean of triplicate determinations, error bars, SD. The experiment was repeated as an independent biological replicate to confirm results. c Monolayer
cultures of human HEPG2 cells in 6-well format were infected with C. albicans and then incubated with the indicated compounds for 48 h (FL, conventional
antifungal fluconazole). Cultures were then fixed and stained by Periodic Acid-Schiff (PAS) technique to visualize fungal burden (dark red/purple signal)
and underlying human cells (light pink signal). Representative fields from conventional light photomicrographs are presented at the same magnification in
all panels. The experiment was repeated in two independent biological replicates to confirm results. Scale bar, 100 μm
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in the treatment of fungal infections. Host defense against inva-
sive infection relies heavily on the ingestion and destruction of C.
albicans by innate immune cells, such as macrophages46. Thus,
we compared the effect of CMLD013075 to that of radicicol on
phagocytosis of C. albicans by macrophages. We pre-treated
Raw264.7 mouse cells for two hours with radicicol or
CMLD013075 then infected cultures with log-phase C. albicans.
After an additional two hours, phagocytosis of the fluorescently
labeled fungi was measured by flow cytometry. Neither com-
pound impaired engulfment of C. albicans by these macrophages
(Fig. 7a). Likewise, both compounds had similar effects in driving
the yeast-to-filament transition reported for classical Hsp90
inhibitors (Fig. 7b). This Hsp90-dependent morphogenetic pro-
gram has an important role in the organism’s virulence and
interactions with host immune effectors such as macrophages12.
In contrast to phagocytosis, Hsp90 inhibitor treatment did
impair macrophage activation as measured by secretion of the
pro-inflammatory cytokines TNF-α and IL-1β. Consistent with its
selectivity for fungal Hsp90, however, CMLD013075 caused far
less suppression than radicicol of cytokine production (Fig. 7c), a
critical requirement for induction of robust immune responses
that aid in the clearing of fungal infections. In addition to effects
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Fig. 7 Sparing of adverse effects on mammalian cells by CMLD013075. a Cultures of a mouse macrophage cell line were pre-incubated with the indicated
concentrations of Hsp90 inhibitors, washed into compound-free medium and infected with a strain of GFP-expressing C. albicans. After an additional 2-h
incubation, engulfment of fungus was monitored by flow cytometry. The percentage of macrophages with internalized C. albicans is plotted relative to no-
compound control for increasing concentrations of inhibitor. Each data point represents the mean of triplicate determinations. Error bars, SD. The
experiment was repeated as an independent biological replicate to confirm results. b Effect of Hsp90 inhibitor exposure on fungal filamentation, a well-
established consequence of Hsp90 inhibition was imaged by differential interference contrast microscopy. Representative fields from micrographs
obtained at the same magnification for all images are presented. Scale bar, 10 µm. The experiment was repeated as an independent biological replicate to
confirm results. c Cultures of a mouse macrophage cell line were pre-incubated with the indicated concentrations of Hsp90 inhibitors, washed into
compound-free medium and infected with a strain of GFP-expressing C. albicans. After additional 2-h incubation, aliquots of medium were removed and
assayed by ELISA for level of the indicated pro-inflammatory cytokines. Each data point depicts the mean derived from three independent cultures. Error
bars, SD. The entire experiment was repeated as an independent biological replicate to confirm results. d Induction of the heat-shock response was
measured in a strain of C. albicans (right) and a mammalian cell line (left). Cells of each species were stably transduced with a plasmid encoding a reporter
protein under transcriptional control of heat-shock promoter elements from an HSP70 gene native to the respective species. Relative concentration-
dependent activation of reporter expression by compounds after overnight (human cells) or 6-h (C. albicans) exposure is plotted. Each point depicts the
mean of three independent wells. Error bars, SD. The experiment in both human and fungal cells was repeated as an independent biological replicate to
confirm results
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on host immune function, we also examined activation of the
evolutionarily conserved heat-shock response by CMLD013075.
Such activation is well-defined toxicity of impairing Hsp90’s
essential role in maintaining protein homeostasis in cells and has
been widely used as a sensitive pharmacodynamic endpoint for
target engagement in the clinical development of Hsp90
inhibitors as anticancer agents47,48. To compare the degree to
which CMLD013075 vs classical Hsp90 inhibitors activated the
heat-shock response, we used cells stably expressing reporter
proteins (β-galactosidase in C. albicans and firefly luciferase in
human 293T kidney-derived cells) under transcriptional control
of heat-shock promoter elements from an HSP70-family gene of
the relevant species. Treatment of human cells with the anticancer
Hsp90 inhibitor ganetespib or radicicol itself drove
concentration-dependent reporter activation as expected.
Although CMLD013075 also activated the reporter, activation
required much higher concentrations of this compound (Fig. 7d).
The opposite pattern of potency held true in C. albicans;
CMLD013075 induced a peak threefold activation of the heat-
shock reporter at 1 μM whereas neither ganetespib nor radicicol
induced the reporter to a measurable extent (Fig. 7d).
Reversal of antifungal drug resistance. To determine whether
CMLD013075 could potentiate antifungal activity in a manner
similar to that previously reported for other Hsp90 inhibitors6,7,
we used a standard dose-response matrix (checkerboard)
approach involving gradients of Hsp90 inhibitor and FL, the most
commonly used clinical antifungal. By Bliss independence mod-
eling analysis49, we found strong synergy for both radicicol (δ=
22.6) and CMLD013075 (δ= 13.0) in combination with FL
against the C. albicans clinical isolate CaCi-2 (Fig. 8a). Given that
azoles such as FL are fungistatic against C. albicans alone but
fungicidal in combination with an Hsp90 inhibitor6,7, we also
performed clonogenic survival assays with CMLD013075 to
determine whether it conserved this important property of Hsp90
inhibition. Using a reference strain of C. albicans, we again per-
formed checkerboard assays titrating FL and CMLD013075. After
48 h in liquid culture (Supplementary Figure 9a), cells were
transferred onto drug-free solid medium to assess viability
(Supplementary Figure 9b). With similar potency, both radicicol
and CMLD013075 transformed the fungistatic azole into a fun-
gicidal combination.
To learn whether CMLD013075 would eliminate the FL-
resistant growth of strain CaCi-2 in a manner similar to that
previously reported for other Hsp90 inhibitors, the wells in plates
that had been previously seeded with luciferized human cells were
infected with GFP-marked CaCi-2. Hsp90 inhibitors were then
added over a range of concentrations in addition to a fixed
concentration of FL. After 48 h at 37 °C, relative fungal burden
was measured by GFP fluorescence and survival/proliferation of
the human cells was evaluated by luminescence. While all Hsp90
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Fig. 8 CMLD013075 reverses antifungal resistance in co-culture. a Checkerboard analysis of antifungal activity for combination of FL with Hsp90 inhibitors.
FL-resistant strain CaCi-2 was exposed to the indicated twofold serial dilutions of each compound for 48 hours. Relative growth inhibition is displayed in
heat-map format. Each colored box represents the mean of duplicate determinations. Color scale for relative growth is provided to the right of panel, green:
no inhibition to black: complete inhibition. The experiment was repeated as an independent biological replicate to confirm results. b Co-culture of
fluconazole (FL)-resistant, GFP-expressing C. albicans strain with human 293T cells line stably expressing a luciferase reporter. The concentration-
dependent inhibition of fungal (left) and human (right) cell growth and survival by Hsp90 inhibitors in the presence of FL was measured in 384-well format
after 48-h treatment. Relative fungal burden was evaluated by plate reader using a fluorescence endpoint while human cell survival was evaluated by
measuring luminescence. Values for each endpoint were normalized to wells receiving no Hsp90 inhibitor. Each point represents the mean of
measurements from triplicate wells. Error bars, SD. The experiment was repeated once as an independent biological replicate to confirm results
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inhibitors displayed comparable activity in sensitizing CaCi-2 to
FL, CMLD013075 was much less toxic than radicicol or
ganetespib to HEPG2 cells in the co-culture environment
(Fig. 8b).
Encouraged by the selective activity of CMLD013075 in co-
culture, we made preliminary investigations into the compound’s
suitability for administration to mice. To do so, we first developed
a sensitive and reliable analytical method to measure levels of the
compound in biological media (Supplementary Figure 10a). We
then measured the stability of the compound in mouse plasma.
As expected, by dampening its Michael reactivity, the oxime
modification in CMLD013075 increased plasma stability com-
pared to radicicol (Supplementary Figure 10b). Unfortunately, the
pendant 4-methoxybenzyl group also increased susceptibility to
P450 metabolism, as reflected by ~80% loss of parent radicicol
oxime after 60-min incubation in mouse liver microsomes. Given
this pharmacological liability, relatively rapid clearance from the
systemic circulation in a single dose pharmacokinetic study of
CMLD013075 in mice was observed (Supplementary Figure 10c).
Further work will be required to improve the whole-animal
pharmacology of our tool compound CMLD013075 before testing
in mice can be pursued. Nevertheless, results so far provide strong
structural evidence and biological proof-of-principle for the
feasibility of targeting Hsp90 in a species-selective manner to
combat invasive fungal disease.
Discussion
Heat-shock proteins, especially Hsp90, are notable for their
exceptional degree of sequence conservation across species.
Despite such conservation, the crystal structures of the C. albicans
Hsp90 NBD presented here revealed sufficient conformational
flexibility to enable synthesis of first a fungal-selective Hsp90
inhibitor. Our proof-of-concept probe molecule CMLD013075
inhibited the growth of C. albicans, enforced filamentous growth
in the absence of an inducing cue, displayed reduced toxicity
against mammalian cell lines and potentiated azole activity
against a drug-resistant clinical isolate of C. albicans.
In initial work, the crystal structures of apo, ADP-bound, and
radicicol-bound fungal NBD showed minimal structural varia-
tion. More problematic, they also showed little variation with
respect to the human NBD. Importantly, however, the region
spanning residues Asp91 to Gly97 of C. albicans NBD in its apo
state was seen in two conformations. We hypothesized that this
observation might result from greater flexibility within the fungal
ATP-binding site than was immediately obvious, an increased
flexibility that might contribute to observed differences in the
intrinsic ATPase activity of the fungal and host homologs24,50.
The significance of this observation, however, became clearer
when we determined structures for the C. albicans NBD in
complex with SNX-2112 and AUY922. The region spanning
residues 93–102 adopted very distinct configurations to accom-
modate each of these compounds. In addition, extensive struc-
tural rearrangements, inclusive of regions outside of the
nucleotide-binding site were observed in the case of AUY922.
In complex with this drug, movement of the NBD lid region was
accompanied by disappearance of the N-terminal β-strand.
Remarkably, previous work in S. cerevisiae has shown that the
first 24 residues of the NBD stabilize it in a rigid state and their
removal confers flexibility specifically to the region between
amino acids 98 and 12051. While no such data are available in
Candida, our findings are consistent with N-terminal alterations
being capable of affecting the architecture of the overall binding
site and vice versa.
Insights gained from the fungal structures reported here
inspired synthesis of derivatives of the natural product radicicol
and its des-chloro variant monocillin I, all synthesized with
the goal of achieving fungal selectivity. We hypothesized that
steric challenges would allow for selective accommodation
by the more flexible fungal NBD. Amongst the analogs,
CMLD013075 showed >25-fold biochemical selectivity for C.
albicans Hsp90 NBD compared with the mammalian homolog.
Importantly, a co-crystal structure for CMLD013075 in complex
with the fungal NBD also showed a major and distinct structural
change associated with inhibitor binding. These changes could be
due to either stabilization of a pre-existing conformation visited
by the NBD during the Hsp90 chaperoning cycle or de novo
induced-fit effects, but both mechanisms are dependent on the
intrinsic protein flexibility52. In the case of CMLD013075, the
orientation of the p-methoxybenzyl group towards the protein’s
core is proposed to support these conformational changes, with
stabilizing hydrophobic and NH⋯π interactions in a newly
formed elongated pocket. This hypothesis is supported by our
mutagenesis results demonstrating that the mutations Leu130Ala
(affecting ligand-binding) and Phe131Tyr (affecting lid region
flexibility) were accompanied by a reduction in the binding affi-
nity of CMLD013075. Notably, these positions are variable in
other fungal pathogens, including C. neoformans and A. fumi-
gatus. Such variation could negatively impact CMLD013075
binding affinity in these species and necessitate additional mod-
ifications in the pursuit of a pan-selective fungal Hsp90 inhibitor.
Given the remarkable conformational shift associated with the
binding of monocillin I-derived CMLD013075, it remains to be
determined whether radicicol-derived analogs (3–5), which
exhibited more modest fungal selectivity and similar whole-cell
bioactivity to CMLD013075, bind in a similar manner. The sole
difference between radicicol and monocillin I is a single chlor-
ination of the aryl ring. Among resorcylate Hsp90 inhibitors,
replacement of this chlorine with moderately sized aliphatic
groups (ethyl, isopropyl) often improves potency, attributed to
enhanced hydrophobic interactions in the lipophilic pocket of the
ATP-binding region, as seen in the C. albicans and human NBD-
AUY922 co-crystals37. The top fungal-selective radicicol-derived
inhibitor, ortho-chlorobenzyl-substituted 4 (2.9-fold selectivity in
lysates, 531 nM EC50, 2.6 μM MIC), would be unable to engage in
hydrophobic interactions as observed at the para-position of the
CMLD013075 benzyl oxime, and halogenation of this ring should
also significantly decrease potential for NH⋯π binding with
Asn40.
Hsp90 orthologue selectivity has been recognized as a pro-
mising toxicity-mitigating strategy to improve the clinical efficacy
of Hsp90 inhibitors in humans53. Several distinct chemotypes
have been shown to take advantage of the differential structural
plasticity intrinsic to each human Hsp90 orthologue, thus
bypassing the limited sequence variation seen in these essential
chaperones54–56. The resorcylate analog CMLD013075 achieves
fungal specificity in an analogous manner, exploiting the exten-
sive structural flexibility of the C. albicans NBD. Nonetheless,
there are significant variations in the structural repertoire avail-
able to the fungal and host chaperones. Both proteins can
accommodate compounds such as SNX-2112 with a limited
remodeling of the binding site. Only the fungal protein, however,
showed remodeling of the N-terminus and lid region to accom-
modate the binding of CMLD013075 and AUY922. The increased
catalytic efficiency of the fungal chaperone compared with the
human protein might well be correlated with its enhanced flex-
ibility, but from the perspective of drug discovery, such con-
formational flexibility also allows access to unique structural
features to generate fungal-selective compounds.
The observed conformational change in the fungal NBD
showed some similarity to the open conformation described for
Grp94 in complex with ADP (r.m.s.d. of 4.337 Å for main-chain
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atoms), and it can be related to an initial conformational change
necessary to accomplish a complete catalytic cycle by the full-
length chaperone57. To investigate orthologue selectivity further,
we also overlaid the structure of our C. albicans-CMLD013075
complex with the structure reported for Grp94 in complex with
PUWS13, a paralogue-selective inhibitor of this chaperone (PDB
code 3O2F)58. Consistent with the 5-fold lower affinity of
CMLD013075 for Grp94 NBD than fungal Hsp90 NBD, however,
these two complexes shared very limited structural similarity (r.
m.s.d. of 8.39 Å for main-chain atoms).
Over the past several decades, an extensive literature has
accumulated characterizing the role of the molecular chaperone
Hsp90 in diverse human diseases including cancer23, neurode-
generative disorders27, and the establishment and maintenance of
infectious diseases32,59. In concert, tremendous efforts have been
made to develop potent and specific drugs with which to target
this chaperone in humans. In oncology, where most if not all
clinical trials have taken place, these compounds have displayed
disappointing activity60. However, based on findings in model
systems ranging from cancer cells to fungi, we suggest the true
therapeutic potential of Hsp90 inhibitors actually lies in com-
bining them with other therapies to alter evolvability and limit the
emergence of drug resistance. The discovery and development of
species-selective Hsp90 inhibitors capable of potentiating current
antifungals in this unique way could make it possible to test this
fundamental hypothesis in patients and help combat the growing
threat of invasive fungal infection. To provide effective ther-
apeutics, however, the challenge of designing inhibitors that are
not only fungal-selective, but also able to access the intracellular
environment and avoid efflux will need to be overcome. Patho-
genic fungi have evolved an array of permeability constraints for
antifungal drugs, via compromised drug import and/or increased
drug efflux61,62. The importance of these constraints is high-
lighted by the disparity between the low nanomolar affinity of
CMLD013075 we demonstrated for Hsp90, and the micromolar
concentrations needed to inhibit whole-organism growth and
survival in culture. Hopefully, despite such pharmacological
challenges, the cross-over approach we adopted in leveraging
extensive anticancer drug discovery/development resources to
advance far less well-funded antimicrobial efforts will encourage
similar efforts on the part of other investigators. Finally, beyond
the specific application of targeting Hsp90, ou\r findings highlight
the value of chemo-structural approaches in overcoming the
broader challenge of selectively targeting members of closely
conserved protein families with high biomedical significance.
Methods
Reagents. The Hsp90 inhibitors SNX-2112 (S2639, >99%) AUY922 (S1069, 99%)
ganetespib (S1159, >99%) were purchased from Selleck Chemicals. Geldanamycin
(ant-gl-5, >95%) was purchased from Invivogen. Fluconazole was obtained from
Sequoia Research Products (SRP01025f, >99%) and Cy3B-Mono NHS ester was
purchased from GE Healthcare UK Ltd (PA63101, >95%). The cell lines HEPG2
(HB-8065), Raw264.5 (TIB-71), 293T (CRL-3216), and 3T3 (NIH/3T3; CRL-1658)
were obtained from the American Type Culture Collection (ATCC) and grown in
DMEM supplemented with 10% fetal bovine serum at 37 °C under 5% CO2.
Cultures were confirmed negative for mycoplasma contamination by monthly
surveillance testing using a PCR-based kit.
Chemical synthesis. See Supplementary Methods for materials, methods, proce-
dures and characterization data for the synthesis of oxime analogs 1–8.
Cy3-labeled geldanamycin (Cy3-GdA) was prepared by reacting geldanamycin
with a 2-fold molar excess of diaminobutane in dimethylformamide34. After clean-
up by silica gel chromatography, amine-derivatized geldanamycin was reacted with
Cy3B-Mono NHS ester and the conjugate purified by silica gel chromatography.
Aliquots were dried down and stored in the dark under argon prior to use in FP
assays.
NBD expression and purification for crystallographic studies. Sequences of the
recombinant NBD used for crystallization and FP binding assays were as follows:
C. albicans Hsp90 (E7-K218)
mhhhhhhssgrenlyfqgETHEFTAEISQLMSLIINTVYSNKEIFLRELISNASDALD
KIRYQALSDPSQLESEPELFIRIIPQKDQKVLEIRDSGIGMTKADLVNNLGTIAK
SGTKSFMEALSAGADVSMIGQFGVGFYSLFLVADHVQVISKHNDDEQYVWES
NAGGKFTVTLDETNERLGRGTMLRLFLKEDQLEYLEEKRIKEVVKKHSEFVAY
PIQLVVTKEVEK Human Hsp90 beta (M1-K223) mhhhhhhssgrenlyfqgMPEEVH
HGEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNASDALDKIRYESLTDP
SKLDSGKELKIDIIPNPQERTLTLVDTGIGMTKADLINNLGTIAKSGTKAFMEA
LQAGADISMIGQFGVGFYSAYLVAEKVVVITKHNDDEQYAWESSAGGSFTV
RADHGEPIGRGTKVILHLKEDQTEYLEERRVKEVVKKHSQFIGYPITLYLEKE
REK
Human Grp94 (A63-I337)
maswhpqfekgaddddkmASQIRELREKSEKFAFQAEVNRMMKLIINSLYKNKEIFL
RELISNASDALDKIRLISLTDENALSGNEELTVKIKCDKEKNLLHVTDTGVGM
TREELVKNLGTIAKSGTSEFLNKMTEAQEDGQSTSELIGQFGVGFYSAFLVAD
KVIVTSKHNNDTQHIWESDSNEFSVIADPRGNTLGRGTTITLVLKEEASDYLE
LDTIKNLVKKYSQFINFPIYVWSSKTETVEEPMEEEEAAKEEKEESDDEAAVEE
EEEEKKPKTKKVEKTVWDWELMNlpfssisahhhhhhhhhh
Recombinant NBDs were produced on small or large-scale using different
methods. For small scale, the protein expression construct was transformed into E.
coli Rosetta2 (Novagen) competent cells. Successful transformants were grown in
LB overnight at 37 °C, these cultures were used to inoculate 1 L Terrific Broth (TB)
cultures. Growth at 37 °C was continued until OD600 reached ~1.0, whereupon
temperature was lowered to 18 °C and protein expression was induced by the
addition of 1 mM isopropyl β-D-thiogalactopyranoside (IPTG). Overnight post-
induction cells were collected by centrifugation and resuspended in binding buffer
(50 mM Hepes pH 7.5, 500 mM NaCl, 5 mM imidazole, 5% glycerol, 1 mM
benzamidine, and 1 mM phenylmethanesulfonyl fluoride (PMSF)) and the
resuspended cells were stored at −80 °C. For large-scale production, transformants
were grown in TB media in a LEX bioreactor system (Harbinger Biotechnology and
Engineering Corp., Ontario, Canada). Overnight starter cultures were allowed to
grow at 37° C until reaching an OD600 value ~5, cooled to 15 °C, and subsequently
induced overnight with 0.5 mM IPTG. Cells were harvested by centrifugation and
cell pellets resuspended in 40 mL of binding buffer per liter of culture, then flash
frozen in liquid nitrogen and stored in −80 °C until needed.
Frozen cells were thawed in 0.5% CHAPS and 500U of benzonase for ~45 min
at room temperature. For large-scale preparations, an additional mechanical lysis
was done using an M-110EH Microfluidizer Processor (Microfluidics Corp., MA,
USA). Cell lysates were then centrifuged to eliminate debris and the cleared lysate
was loaded onto a DE52 anion exchange resin column (Whatman, MA, USA)
followed by a 2 mL Ni-NTA column (Qiagen, MD, USA). This column was then
washed with 200 mL of a buffer consisting of 50 mM HEPES, pH 7.5 with 500 mM
NaCl, 30 mM imidazole, and 5% glycerol. The protein was eluted with 7–15 mL of
a buffer consisting of 50 mM HEPES, pH 7.5 with 500 mM NaCl, 250 mM
imidazole and 5% glycerol. Following elution, 1 mM EDTA and 1mM TCEP were
added to the sample. The protein was further purified by size exclusion
chromatography on a Superdex 200 (GE Healthcare, NJ, USA) column equilibrated
with buffer consisting of 50 mM HEPES, pH 7.5 and 500 mM NaCl. The protein
was concentrated in an Amicon Ultra centrifugal filter device (Millipore, MA,
USA) and its identity was confirmed by SDS-PAGE and mass spectroscopy.
Protein crystallization and structure determination. Aliquots of purified
recombinant C. albicans Hsp90 N-terminal domain (NTD) were crystallized at
21 °C using a sitting-drop vapor-diffusion method, either alone (apo) or in the
presence of five different ligands, ADP, radicicol, CMLD013075, SNX-2112 and
AUY922. Crystals were obtained by mixing one part of protein solution at 10–15
mg/mL (10 mM HEPES, pH 7.5 with 500 mM NaCl, 2 mM TCEP and 4 mM
MgCl2) with or without 2 mM ligand with one part of reservoir solution. In the case
of apo and ADP co-crystals, the reservoir solution contained 2M ammonium
sulfate, 2% PEG400, 100 mM HEPES, pH 7.5. For radicicol co-crystals, the reser-
voir solution contained 8% Tacsimate, pH 5.0 and 20% PEG3350; for
CMLD013075 it included, 5 mM CoCl2, 12% PEG3350, 100 mM HEPES, pH 7.5;
for the SNX-2112 complex crystals it contained, 200 mM MgCl2, 100 mM bis-Tris,
pH 6.5, and 25% PEG3350. Finally, for the AUY922 complex crystals it contained,
20 mM MgCl2, 100 mM HEPES, pH 7.5, and 22% polyacrylic acid sodium salt.
Crystals appeared within one week and were cryo-protected with 20–25% ethylene
glycol or glycerol supplemented mother liquor before being flash cooled in liquid
nitrogen.
Diffraction data were collected using home X-ray sources for the apo and ADP
structures. A synchrotron X-ray source (beamline 08ID-1 at the Canadian Light
Source (CLS)) was used for radicicol and CMLD013075 complexes. Beamline
23ID-D at APS - Argonne National Laboratory was used for SNX-2112 and
AUY922 complexes. Data were processed with HKL300063,64. Structures were
determined by molecular replacement using the yeast Hsp90 NBD (PDB code
1AH8)65 as a search model for the first complex structure of the C. albicans Hsp90
NBD. This structure was used as the model for subsequent structures. Phaser66 was
used for molecular replacement calculations, while model building was performed
with COOT67 and structures were refined with Phenix68. The radicicol and SNX-
2112 complex crystals were twinned, and xtriage (as implemented in Phenix)69
identified the following merohedral twin law h,-k,-l and a twin fraction of ~ 0.3
for both crystals. The positions of all compounds in the reported C. albicans
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Hsp90-ligand complex crystal structures were unambiguous as indicated by their
simulated annealing OMIT maps (Figure S11). CMLD013075 coordinates and
geometry restraints were created within the ELBOW. The stereochemistry of both
models was checked by MOLPROBITY70. Relevant data collection and refinements
statistics are shown in Table S1. Protein structure superpositions were calculated
with LSQKAB71 as implemented in CCP472. Protein structure figures were
generated using UCSF Chimera package73. C. albicans and human Hsp90-AUY922
2D interaction diagrams (Figure S4b bottom panels) were generated using Maestro
(Schrödinger Release 2016–1: Maestro, Schrödinger, LLC, New York, NY, 2016).
Yeast strains and culture conditions. Archives of all yeast strains were main-
tained at −80 °C in 25% glycerol. Strains used in experiments were maintained on
solid (2% agar) yeast extract peptone (YPD, 1% yeast extract, 2% bactopeptone, 2%
glucose) at 4 °C for no more than one month. For experiments, yeast strains were
routinely grown in either YPD medium, unless otherwise indicated. Strains used in
this study are listed in Supplementary Table 4. Strain construction is described
in Supplementary Methods.
Plasmid construction. Recombinant DNA procedures were performed according
to standard protocols and construction of vectors is described in Supplementary
Methods Supporting Information. Plasmids were sequenced to verify the absence
of any nonsynonymous mutations. Plasmids used in this study are listed in Sup-
plementary Table 5. Oligonucleotides used in this study are listed in Supplementary
Table 6.
Minimum inhibitory concentration assays. Antifungal tolerance and resistance
were determined in flat bottom, 96-well microtiter plates using a modified broth
microdilution protocol as described8,10. All Hsp90 inhibitors were formulated in
dimethyl sulfoxide (DMSO, Sigma Aldrich Co.); fluconazole was dissolved in sterile
ddH2O. Each strain was tested in duplicate on at least two occasions. MIC data
were quantitatively displayed in heat-map format using the program Java TreeView
1.1.3 (http://jtreeview.sourceforge.net). To test for fungicidal activity, cultures from
MIC plates were spotted on YPD agar plates using a spotter (Frogger, V&P Sci-
entific, Inc). Plates were photographed after 48 h of incubations at 30 °C.
Preparation of whole-cell lysates for FP assays. To prepare human cell lysate,
approximately 1 × 107 HEPG2 or 3T3 cells were collected by centrifugation at 4 °C,
washed in cold PBS and resuspended in 250 μL binding buffer (20 mM HEPES pH
7.5, 50 mM KCl, 5 mM MgCl2, 0.01% Triton X-100) supplemented fresh with a
protease inhibitor cocktail tablet (Roche; 1183617001), phosphatase inhibitor tablet
(Roche; 04906837001), 20 mM Na2MoO4, and 1 mM DTT. After vortexing, cell
lysate was frozen at −80 °C for 2 h, followed by thawing on ice. The vortex-freeze-
thaw step was repeated. Complete lysis was confirmed by microscopy followed
by centrifugation at 14,000 rpm for 30 min at 4 °C. To prepare yeast lysates, an
overnight culture grown in YPD was diluted to an OD600 of 0.15 in 1 L of pre-
warmed YPD. This culture was grown for 4 h at 37 °C, then centrifuged at
4000 rpm for 20 min at 4 °C. The pellet was resuspended in 10 mL of the same
binding buffer used to prepare mammalian lysate, passed twice through a French
Press and then centrifuged at 14,000 rpm for 30 min at 4 °C. Post centrifugation,
yeast and mammalian lysates were filtered (0.22 μm), supplemented with sterile
glycerol to a final concentration of 15% (v/v), flash frozen, and stored at −80 °C for
up to 5 months. Aliquots were thawed immediately prior to use.
FP assays. Total protein concentration of human and yeast lysates was determined
by Bradford assay as described previously8. Titrations of Cy3-GdA probe and lysate
were evaluated to define conditions that resulted in 75% maximal probe polar-
ization with no competitor present. Serial dilutions of test Hsp90 inhibitors were
then assayed under these same conditions to monitor loss of fluorescence polar-
ization as an indicator of probe displacement from Hsp90. All determinations were
performed in duplicate wells using 384-well black flat-bottom microtiter plates
(Greiner Bio-One; 655076). Titrations of test compound in 25 μL of binding buffer
(supplemented with 0.1 mg/mL bovine gamma globulin), were mixed with an equal
volume of freshly prepared whole-cell lysate spiked with Cy3-GdA (0.1 nM). Plates
were incubated at room temperature for 4–5 h to achieve equilibrium binding for
the geldanamycin-based probe35. Signal in millipolarization (mP) units was mea-
sured at an excitation wavelength of 535 nm and emission wavelength of 595 nm in
a SpectraMax i3 microplate reader (Molecular Devices) using Softmax Pro software
(version 5.4.1). Each experiment was repeated in at least biological duplicate. Non-
linear 4-parameter curve fitting of raw displacement data was performed in
GraphPad Prism 5.0 to determine EC50 values as a measure of relative Hsp90-
binding affinity. Results were normalized to the value determined for GdA in lysate
of each cell type. To determine assay-independent inhibitory Ki values for com-
pounds by FP, the binding affinity of Cy3-GdA probe (0.1 nM) for each NBD
(human and yeast Hsp90 10 nM; human Grp94 7.5 nM) was first determined by
saturation binding measurements33. Using these values, data from equilibrium
competition binding experiments were then analyzed by methods that take into
account the non-ligand saturated conditions inherent to FP assays to calculate the
Ki of inhibitors33.
Microscopy. C. albicans strain SN95 was sub-cultured to an OD600 of 0.1 and
grown for 6 h in the absence or presence of Hsp90 inhibitors as indicated. Imaging
of cells cultured in liquid was performed by differential interference contrast
microscopy with a Zeiss Axio Imager.MI and Axiovision software (Carl Zeiss, Inc.).
Mammalian cell toxicity. Cancer cells were plated in 96-well format at a density of
5000 per well (HEPG2) or 2000 per well (Raw264.7) in DMEM supplemented with
10% fetal bovine serum (FBS) and 1× Pen-Strep antibiotic. Non-tumorigenic
mouse 3T3 fibroblasts were plated in 384-well format at 2500 per well. After
overnight incubation, two-fold dilutions of test compounds were added to wells for
72 h followed by measurement of relative viable cell number using standard
resazurin dye-reduction assay and microplate fluorometer (Tecan Infinite
M1000Pro, 544 nm excitation and 590 nm emission) as previously published74.
Phagocytosis assay. The ingestion of GFP-marked C. albicans CaCi-2 (CaLC867,
Table S4) by mouse macrophages was monitored using flow cytometry. Raw264.7
macrophage cultures were pre-treated with various concentrations of Hsp90
inhibitors for 2 h at 37 °C and then infected with fungus at a multiplicity of
infection of ~2 for an additional 2 h. Wells were harvested by trypsinization and
resultant cell suspensions incubated with Guava ViaCount reagent per manu-
facturer’s recommendation (Millipore Sigma, Cat #4000-0040). Red fluorescent
signal was used to identify macrophages while green fluorescent signal identified
the fungus. Dual positive (red and green) events with appropriate forward- and
side-scatter parameters were quantitated as representative of ingestion of fungus by
a macrophage. All determinations were performed in triplicate and the experi-
mental design was repeated twice.
Cytokine production. Raw264.7 cells were plated in 100 μL of media (DMEM
supplemented with 10% fetal bovine serum (FBS) and 1X Pen-Strep antibiotic) at a
density of 1.5 × 105 cells per well in a 96-well plate. The next day, cells were treated
with a dilution series of radicicol or CMLD013075. After 2 h incubation at 37 °C,
medium was flipped off and wells washed two times with 200 μL of warm medium.
During incubation of macrophages with Hsp90 inhibitor, a culture of C. albicans
grown in YPD overnight at 30 °C was spun down and washed twice with PBS. Cell
counts were then determined using a hemocytometer and an inoculum of 6 × 105
cells per well was added to the macrophages. Co-culture incubation time was 2 h
for measuring secretion of TNF-α and 5 h for measuring IL-1β cytokine levels. To
monitor IL-1β production, macrophages were primed with 50 ng/mL of LPS
(Sigma; L2630) for 2 h prior to infection with C. albicans. At the end of each
experiment 150 mL of media was removed and added to a new 96-well plate that
contained a 25 µL of solution of 7× protease inhibitors in water. The plate was
frozen and stored at −80 °C until measurement of cytokine levels using ELISA kits
from R&D Systems: TNF-α DuoSet (DY410) and IL1-1β/IL-1F2 DuoSet (DY401).
Heat-shock induction assays. Concentration-dependent activation of the heat-
shock response in human cells by Hsp90 inhibitors was measured in 96-well format
as previously published using 293T cells stably transduced with a reporter con-
struct encoding GFP-luciferase fusion protein under transcriptional control of
heat-shock elements from the HSP70B gene74. Activation of the response in C.
albicans was also measured in 96-well format using a reporter strain (CaLC922)
engineered with HSP70 promoter elements driving expression of the LacZ gene
from Streptococcus thermophilus integrated at the HSP70 locus with the URA3
marker for selection. After culture for 2 h in the presence of serial dilutions of
Hsp90 inhibitor, the induction of galactosidase activity was measured using
luminescent Gal-Screen reagent per manufacturer’s recommendations (Applied
Biosystems; Bedford, MA Cat#T1029).
Co-culture experiments. Monolayers of HEPG2 cells established in 6-well format
were infected with log-phase C. albicans (CaCi-2) at a concentration of 2.5 × 103
cells/mL in DMEM supplemented with 5% fetal bovine serum and pen-strep
antibiotic. After addition of test compounds, culture was continued for 48 h. Wells
were fixed in 10% formalin, stained with a periodic acid-Schiff reagent kit (Sigma,
395B-1KT) per manufacturer’s recommendation and photomicrographs obtained
under standard white light illumination. To quantitate the concentration-dependent
toxicity of Hsp90 inhibitors in human-fungal co-cultures, 293T cells stably
expressing firefly luciferase were plated in 384-well format (2000 cells in 20 µL per
well, black clear-bottom plates) and allowed to adhere overnight. Wells were then
infected with log-phase GFP-marked CaCi-2 (CaLC867, 2.5 × 103 cells/mL) in an
equal volume of medium supplemented with fluconazole (4 µg/mL). After 48 h,
medium was replaced with PBS and relative fluorescence per well measured on a
plate reader (Tecan Infinite M1000Pro, 480 nm excitation and 540 nm emission).
Steady-Glo luciferase assay reagent (10 µL per well, Promega Cat# E2520) was then
added, plates incubated at room temperature for 10 mins and relative luminescence
per well measured using an Envision plate reader (Perkin Elmer).
Pharmacological studies. See Supplementary Methods for materials, methods and
instrumentation used to evaluate the metabolic stability in vitro and single dose
plasma pharmacokinetic profile in mice of CMLD013075. Pharmacokinetic studies
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in mice were performed in an ethical manner under animal study protocol 0516-
037-19 as reviewed and approved by the Massachusetts Institute of Technology
Committee on Animal Care (CAC).
Statistical methods. GraphPad Prism 5 and 7.0 were used to perform curve
fitting, calculate EC50 values and generate graphical displays. Technical replicate
numbers (n values) for all quantitative data characterizing the biochemical and
biological activities of compounds are provided in the relevant figure legends.
Informative biological experiments and compound binding measurements were
repeated at least once in an independent experiment to confirm results.
Data availability
The coordinates for NBD structures and their structure factors have been deposited
with the Protein Data Bank (http://www.pdb.org) under the following accession
codes: 6CJI (apo), 6CJJ (ADP), 6CJL (radicicol), 6CJP (CMLD013075), 6CJR (SNX-
2112), 6CJS (AUY922). The source data and calculations underlying Figs. 2a, b, 3b,
4c, Supplementary Figures 3a-c and 7b are provided within the “Source Data” Excel
file associated with the manuscript. Other data are available from the
corresponding author upon reasonable request.
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